Patents by Inventor Amer Mirza

Amer Mirza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3
    Patent number: 11098111
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 24, 2021
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies Specific for TGF-Beta
    Publication number: 20190315850
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-?
    Patent number: 10358486
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 23, 2019
    Assignee: XOMA Technology, Ltd.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies Specific for TGF-Beta
    Publication number: 20180057578
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: June 14, 2017
    Publication date: March 1, 2018
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • TGF-beta-specific antibodies and methods of use thereof for treatment
    Patent number: 9714285
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 25, 2017
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies Specific for TGF-Beta
    Publication number: 20150322146
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: July 24, 2015
    Publication date: November 12, 2015
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies specific for TGF-? and methods of treatment thereof
    Patent number: 9145458
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 29, 2015
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • PRLR-SPECIFIC ANTIBODY AND USES THEREOF
    Publication number: 20150175705
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: March 3, 2015
    Publication date: June 25, 2015
    Inventors: Jason Damiano, Mohammad Luqman, Linda Masat, Amer Mirza, Genevieve Nonet, Daniel Bedinger
  • PRLR-specific antibody and uses thereof
    Patent number: 9005614
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 14, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • Antibodies Specific for TGF-Beta
    Publication number: 20140023644
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 23, 2014
    Applicant: XOMA Technology Ltd.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies specific for TGF-beta and methods for treating thereof
    Patent number: 8569462
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: October 29, 2013
    Assignee: Xoma Technology Ltd.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Antibodies Specific for TGF-Beta
    Publication number: 20120315282
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 13, 2012
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: DANIEL BEDINGER, SHIREEN S. KHAN, AMER MIRZA, AJAY J. NARASIMHA, TOSHIHIKO TAKEUCHI
  • PRLR-Specific Antibody and Uses Thereof
    Publication number: 20110150760
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 23, 2011
    Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: JASON DAMIANO, MOHAMMAD LUQMAN, DANIEL BEDINGER, LINDA MASAT, AMER MIRZA, GENEVIEVE NONET
  • PRLR-specific antibody and uses thereof
    Patent number: 7867493
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: January 11, 2011
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • PRLR-Specific Antibody and Uses Thereof
    Publication number: 20080292620
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: August 17, 2007
    Publication date: November 27, 2008
    Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet